stockrowSotera Health Company
SHC Healthcare Diagnostics & Research
Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024.
- Revenue
- +4.36%
- EPS
- +20.1%
- Free cash flow
- +65.0%
- Total debt
- +0.14%
Quarter to September 2026, against a year earlier
Follow SHC
Alert me
Sotera Health Company (SHC) Current ratio
Sotera Health Company's current ratio at the end of the quarter to 30 September 2026 was 3.1×, up 0.7× from fiscal 2025 (2.5×). Over the past ten years it has ranged from 0.8× (fiscal 2022) to 2.8× (fiscal 2024); the current reading is higher than 88% of that period. That is above the Diagnostics & Research industry median of 2.3× and in line with the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 2.5× | (10.76%) |
| FY2024 | 2.8× | 14.00% |
| FY2023 | 2.4× | 196.47% |
| FY2022 | 0.8× | (62.04%) |
| FY2021 | 2.1× | (4.19%) |
| FY2020 | 2.2× | 10.08% |
| FY2019 | 2.0× | (6.73%) |
| FY2018 | 2.2× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 3.1× | 12.10% |
| Jun 2026 | 2.8× | (0.86%) |
| Mar 2026 | 2.8× | 14.73% |
| Dec 2025 | 2.5× | 3.10% |
| 23 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| BLLN BillionToOne, Inc. compare | 11.2× |
| GRAL GRAIL, Inc. compare | 8.9× |
| VCYT Veracyte, Inc. compare | 5.6× |
| ADPT Adaptive Biotechnologies Corporation compare | 4.0× |
| NEO NeoGenomics, Inc. compare | 3.5× |
| SHC Sotera Health Company | 3.1× |
| QGEN QIAGEN N.V. compare | 2.8× |
| CDNA CareDx, Inc. compare | 2.3× |
| RDNT RadNet, Inc. compare | 1.5× |
| Diagnostics & Research industry median | 2.3× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on SHC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement